VERICI DX PLC ORD GBP0.001VERICI DX PLC ORD GBP0.001VERICI DX PLC ORD GBP0.001

VERICI DX PLC ORD GBP0.001

No trades
See on Supercharts

VRCI fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. It offers the following products for clinical validation and commercialization: Clarava and Tuteva. The Clarava product is a pre-transplant prognosis for the risk of early acute rejection. The Tuteva product is a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels. The company was founded on April 22, 2020 and is headquartered in Franklin, TN.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
VRCI has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company